Evidence map›Paper›PMID 41716746›Full record

ArticleJHEP reports : innovation in hepatology2026

Factors associated with protection from MASLD in type 2 diabetes: A prospective study integrating longitudinal MRI/MRE and stable isotope tracing.

Federica Tavaglione, Veeral Ajmera, Luis Antonio Díaz, Kelvin Li, Egbert Madamba, Ricki Bettencourt, Lisa Richards, Marc Hellerstein, Rohit Loomba

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Federica TavaglioneMASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, United States.
Veeral AjmeraMASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, United States.
Luis Antonio DíazMASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, United States.
Kelvin LiDepartment of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, California, United States.
Egbert MadambaMASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, United States.
Ricki BettencourtMASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, United States.
Lisa RichardsMASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, United States.
Marc HellersteinDepartment of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, California, United States.
Rohit LoombaMASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Type 2 diabetes is one of the strongest risk factors for the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). In this study, we aimed to identify factors associated with protection from MASLD in a prospective cohort of individuals with type 2 diabetes. Methods: This prospective study included 148 individuals with type 2 diabetes who underwent advanced liver phenotyping using MRI and MRE techniques at baseline and 2-year follow-up. Protection from MASLD was defined as the absence of hepatic steatosis (MRI-proton density fat fraction <5%) and significant fibrosis (MRE <3 kPa) at both time points. Factors associated with protection from MASLD were assessed using Firth's penalized logistic regression. Regularized logistic regression models were fitted as complementary analyses. Results: The mean (SD) age and BMI were 65 (8) years and 30.4 (4.3) kg/m Conclusions: Managing modifiable risk factors, such as body weight and lipid profile, may be critical for preventing MASLD development in individuals with type 2 diabetes. Impact and implications: Understanding factors conferring protection from metabolic dysfunction-associated steatotic liver disease (MASLD) in individuals with type 2 diabetes represents a novel research avenue which has not been systematically explored. In this prospective cohort of 148 individuals with type 2 diabetes undergoing advanced liver phenotyping at baseline and 2-year follow-up, we identified lower BMI, lower HOMA-IR, and lower circulating triglycerides as the strongest predictors of remaining free of MASLD. Additionally, by performing an exploratory analysis in an independent cohort of 11 individuals with type 2 diabetes with tracer data, we found that lower hepatic

Indexed as

body mass indexde novo lipogenesisinsulin resistanceNAFLD/MASLDtriglycerides

Identifiers

PMID41716746
PMCPMC12914784

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.